Targeting the tumor stroma for cancer therapy
M Xu, T Zhang, R Xia, Y Wei, X Wei - Molecular Cancer, 2022 - Springer
Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade
Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …
human cancers; however, it remains incompletely understood how tumor-reactive T cells …
First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 …
HJ Lenz, E Van Cutsem, M Luisa Limon… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …
agent or in combination with ipilimumab in patients with microsatellite instability …
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
Anti-PD-1 treatment has shown unprecedented clinical success in the treatment of non-small-
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …
The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment
SK Kim, SW Cho - Frontiers in pharmacology, 2022 - frontiersin.org
Recently, in the field of cancer treatment, the paradigm has changed to immunotherapy that
activates the immune system to induce cancer attacks. Among them, immune checkpoint …
activates the immune system to induce cancer attacks. Among them, immune checkpoint …
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international …
L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker… - The Lancet …, 2021 - thelancet.com
Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …
Targeting metastatic cancer
K Ganesh, J Massague - Nature medicine, 2021 - nature.com
Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …
cause of cancer death. Recent work has uncovered the unique biology of metastasis …